BGLC: RM1.2 MLN INVESTMENT IN AISB TO ADVANCE AI ADOPTION, REVOLUTIONISING HEALTHCARE

KUALA LUMPUR, April 19 (Bernama) -- BioNexus Gene Lab Corporation (BGLC) has announced a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company.

According to a statement, this investment underscores BGLC’s commitment to advancing healthcare solutions through cutting-edge artificial intelligence (AI) and predictive analytics.

“Our investment in AISB reflects our belief in their transformative healthcare solutions. Together, we aim to revolutionise patient care through predictive and generative AI,” said BGLC Chief Executive Officer (CEO), Sam Tan.

Meanwhile, AISB CEO, Andrew Teng said: “We welcome MRNA Scientific’s support and looked forward to leveraging their expertise. The future of healthcare lies in predictive analytics and personalised solutions.”

MRNA Scientific’s investment of RM1.2 million (approximately US$250,000) will occur in two tranches and it has made an initial payment of approximately RM100,000 to be followed by a final payment of RM1.1 million, subject to a formal agreement.

The investment in AISB signifies a strategic move to accelerate healthcare innovation and is expected to constitute an indicative equity of approximately 10 per cent of the ordinary shares in AISB upon completion.

The infusion of capital will further AISB’s development and accelerate its AI rollout including AI Assistance in the clinic and on-app as well as predictive analytics and personalised solutions.

MRNA Scientific and BGLC believe that this strategic investment will allow BGLC’s Blood-based Genomic Screening liquid biopsies and other diagnostic services to be better marketed and accessible to a wider range of customers and healthcare providers.

A wholly-owned subsidiary of BGLC, MRNA Scientific specialises in blood-based genomic screening and dynamic genome profiling in which its innovative techniques enable early disease detection, personalised health management, as well as AI-driven insights.

-- BERNAMA